Water-Soluble Temozolomide Derivatives and Polymer-Temozolomide Conjugates for Enhanced Glioblastoma Treatment
PRODUCT OPPORTUNITIESInjectable formulations of small-molecule temozolomide derivatives for treating Glioblastoma MultiformeInjectable formulations of temozolomide-polymer conjugates for treating Glioblastoma MultiformePRODUCT OPPORTUNITIES ADVANTAGESThe new small-molecule temozolomide derivatives and polymer-temozolomide conjugates have significantly enhanced aqueous solubility.The conjugates provide opportunities for improving temozolomide pharmacokinetics, extending drug lifetime in circulation, reducing off-target toxicity, and enhancing targeting to glioblastoma tumor tissue. TECHNOLOGY DESCRIPTIONThis invention provides novel compositions of water-soluble small molecule temozolomide derivatives and water-soluble polymer-temozolomide conjugates for enhanced treatment of glioblastoma multiforme. ABOUT THE LEAD INVENTORDr. Todd Emrick is a Professor in the Department of Polymer Science and Engineering. He is a prolific inventor and a Fellow of the National Academy of Inventors. AVAILABILITY: Available for Licensing and/or Sponsored Research DOCKET: UMA 16-066 PATENT STATUS: Patent Pending NON-CONFIDENTIAL INVENTION DISCLOSURE LEAD INVENTOR: Todd S. Emrick, Ph.D. CONTACT: This invention provides novel compositions of water-soluble small molecule temozolomide derivatives and water-soluble polymer-temozolomide conjugates for enhanced treatment of glioblastoma multiforme.
美国
